Overexpression of PIK3CA impacts global survival of patients with HER2 subtype breast carcinoma
dc.contributor.author | Felicidade, Sidnei Iensen | pt_BR |
dc.contributor.author | Pilar, Emily Ferreira Salles | pt_BR |
dc.contributor.author | Teixeira, Joara Predebom Flores | pt_BR |
dc.contributor.author | Watte, Guilherme | pt_BR |
dc.contributor.author | Remonatto, Gabriela | pt_BR |
dc.contributor.author | Alves, Rita de Cássia Sant’Anna | pt_BR |
dc.contributor.author | Roehe, Adriana Vial | pt_BR |
dc.date.accessioned | 2021-05-13T04:26:33Z | pt_BR |
dc.date.issued | 2020 | pt_BR |
dc.identifier.issn | 1107-0625 | pt_BR |
dc.identifier.uri | http://hdl.handle.net/10183/220832 | pt_BR |
dc.description.abstract | Purpose: To investigate the expression of proteins fosfatidilinositol-4,5-bifosfate 3-quinase (PIK3CA) and phosphatase and tensin homolog (PTEN) in HER2-positive breast cancer and verify their associations with clinical and pathological variables. Methods: We assessed PTEN and PIK3CA status using immunohistochemistry (IHC), which was performed in formalin-fixed paraffin-embedded biopsies from 50 patients with HER2-positive breast cancer. Medical records were studied for collection of clinical-pathological information, including overall survival (OS). The HIC markers PTEN and PIK3CA were analyzed semi-quantitatively by two blinded independent researchers. The relationship between the variables were evaluated using the chi-square test and Kaplan-Meier curves plus log-rank test for survival. Results: In IHC, the expression level of PIK3CA was 86%, and loss of PTEN expression was observed in 46% of the cases. The expression of the markers showed no significant correlation with each other or with the clinical and pathological parameters studied: tumor grade, staging, ER, PR, Ki67 and recurrence. The highest expression of PIK3CA was associated with lower number of deaths (p=0.016) and longer OS of patients (p=0.001). The PTEN marker showed no significant effect on OS. Conclusions: The PIK3CA expression showed a protective effect in relation to the OS of patients with HER2-positive breast cancer. | en |
dc.format.mimetype | application/pdf | pt_BR |
dc.language.iso | eng | pt_BR |
dc.relation.ispartof | JBUON. Acharnes. Vol. 25, no. 6 (2020), p. 2546-2551 | pt_BR |
dc.rights | Open Access | en |
dc.subject | Neoplasias da mama | pt_BR |
dc.subject | Breast cancer | en |
dc.subject | Imuno-histoquímica | pt_BR |
dc.subject | Immunohistochemistry | en |
dc.subject | HER2 | en |
dc.subject | Sobrevida | pt_BR |
dc.subject | PIK3CA | en |
dc.subject | Biomarcadores | pt_BR |
dc.subject | PTEN | en |
dc.subject | Survival | en |
dc.title | Overexpression of PIK3CA impacts global survival of patients with HER2 subtype breast carcinoma | pt_BR |
dc.type | Artigo de periódico | pt_BR |
dc.identifier.nrb | 001121681 | pt_BR |
dc.type.origin | Estrangeiro | pt_BR |
Este item está licenciado na Creative Commons License
![](/themes/Mirage2Novo//images/lume/cc.png)
-
Artigos de Periódicos (39402)Ciências da Saúde (10592)